Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF plus Entecavir in Chronic Hepatitis B
NCT03164889Terminated
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Jan 2017
- Primary completion
- Jan 2018
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Randomised, open-label trial of granulocyte macrophage-colony stimulating factor in Chronic Hepatitis B (CHB) (2 arms), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoint: Rate of HBsAg loss at 48 weeks. Started Jan 2017; status: terminated.
02
Drugs
granulocyte macrophage-colony stimulating factor
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03164889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03164889.